Autobacs Seven Co., Ltd.

As of March 31, 2026, Autobacs Seven Co., Ltd. carries a market capitalization of 122.98B, placing it among publicly traded companies globally. Its enterprise value stands at 141.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Autobacs Seven Co., Ltd.'s next confirmed earnings release is scheduled for October 30, 2026.

As of March 31, 2026, Autobacs Seven Co., Ltd. has 78.53M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Autobacs Seven Co., Ltd. maintains a current ratio of 1.96, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Autobacs Seven Co., Ltd.'s stock has declined approximately 3.29% over the past 52 weeks. The 50-day moving average sits at 1,553.94, while the 200-day moving average is 1,567.44.

As of March 31, 2026, Autobacs Seven Co., Ltd. holds 23.44B in cash and equivalents against 41.31B in total debt, resulting in a net debt position of 18.38B. Total book value stands at 136.25B, with working capital of 59.80B providing operational flexibility.

Autobacs Seven Co., Ltd.'s most recent stock split took place on March 27, 2013 with a 1:3 split ratio.